| Name | Title | Contact Details |
|---|---|---|
Amar Murugan |
Senior Vice President and General Counsel | Profile |
Sarah Soifer |
Director, Compliance Counsel | Profile |
Mark Kresnak |
Assistant General Counsel of Intellectual Property | Profile |
Mina Kim |
General Counsel | Profile |
Mina Kim |
General Counsel | Profile |
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining.
Sigtem Technology Inc is a Harleysville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.